BeyondSpring (NASDAQ:BYSI - Get Free Report) announced its earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, Zacks reports.
BeyondSpring Price Performance
NASDAQ BYSI traded up $0.02 on Monday, reaching $1.70. The company's stock had a trading volume of 13,252 shares, compared to its average volume of 29,333. BeyondSpring has a twelve month low of $0.98 and a twelve month high of $3.63. The firm's 50 day moving average is $1.52 and its two-hundred day moving average is $1.67.
About BeyondSpring
(
Get Free Report)
BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BeyondSpring, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeyondSpring wasn't on the list.
While BeyondSpring currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
